SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : King Pharmaceuticals, Inc. (Nasdaq:KG)(Was KING) -- Ignore unavailable to you. Want to Upgrade?

To: gregor who wrote (34)9/3/2000 10:37:24 AM
From: babette spatz  Read Replies (1) | Respond to of 61
 
O.K. JMED was awash with cash. KG has big debts. Now that more money is available, will it return to a negative cash position. Also, JMED grew by acquisition. What is KG's plan? If the democrats have their way, most pharmaceutical
companies will suffer.



To: gregor who wrote (34)3/7/2001 11:09:27 AM
From: radman33  Read Replies (2) | Respond to of 61
 
Anyone still following King? It appears that Altace is growing nicely with accelerating growth to follow. My only question is this: when does the patent expire?

Thanks,
Jay


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News